New York Assembly Bill A06087

New York 2025-2026 Regular Session

• Introduced: 2/26/25
• Refer: 2/26/25
• Refer: 1/7/26

Caption

Requires health insurance policies to fully cover multi-marker testing related to ovarian cancer to patients which have been diagnosed with an ovarian adnexal mass.

Summary

Bill A06087 mandates that health insurance policies in New York must provide full coverage for multi-marker testing related to ovarian cancer for patients diagnosed with an ovarian adnexal mass. This legislation aims to ensure that patients have access to necessary diagnostic testing without the burden of out-of-pocket costs, as the coverage will not be subject to annual deductibles or coinsurance. The bill amends sections of the insurance law and social services law to implement these requirements, thereby enhancing patient care and early detection of ovarian cancer.

Impact

If enacted, this bill will significantly alter the landscape of health insurance coverage for ovarian cancer testing in New York. It will require insurers to absorb the costs of multi-marker testing, which could lead to increased premiums or changes in policy offerings. The legislation is expected to improve patient outcomes by facilitating earlier diagnosis and treatment options for women affected by ovarian cancer, thus potentially reducing long-term healthcare costs associated with late-stage cancer treatment.

Sentiment

The sentiment surrounding Bill A06087 appears to be largely supportive, reflecting a growing recognition of the importance of comprehensive cancer care and the need for accessible testing options. However, there may be concerns from insurance providers regarding the financial implications of mandated coverage, which could lead to debates about the sustainability of such requirements.

Contention

Notable points of contention may arise from insurance companies that argue against the financial burden of mandatory coverage for multi-marker testing. They may express concerns about the potential for increased premiums and the impact on their overall business model. Advocates for women's health and cancer awareness groups, on the other hand, are likely to support the bill, emphasizing the importance of early detection and comprehensive care for ovarian cancer.